The World In A Grain Of Sand

The World in a Grain of Sand: Verve Therapeutics

Listen Later

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive into:

  • Base editing, and its advantages over traditional (potentially error-prone) CRISPR.
  • Verve’s pipeline, including their strategy of starting with genetically well-defined diseases like familial hypercholesterolemia and then expanding to the general population of patients with atherosclerotic cardiovascular disease.
  • Verve’s approach for predicting off-target gene editing, a key challenge for the gene editing field.
  • Verve’s unique licensing strategy with Beam, Acuitas, and the Broad to secure several foundational technologies.
  • The competitive landscape and target product profile tradeoffs for one-and-done gene editing approaches vs other therapeutic modalities.
  • and more.

    • For updates from KdT, ⁠subscribe to our Substack⁠.

    ...more
    View all episodesView all episodes
    Download on the App Store
    The World In A Grain Of SandBy KdT Ventures
    • 5
    • 5
    • 5
    • 5
    • 5

    5

    19 ratings

    More shows like The World In A Grain Of Sand

    View all
    The Bill Simmons Podcast by The Ringer

    The Bill Simmons Podcast

    30,112 Listeners

    The Long Run with Luke Timmerman by Timmerman Report

    The Long Run with Luke Timmerman

    116 Listeners

    Business Of Biotech by Matt Pillar

    Business Of Biotech

    82 Listeners